The test maps 150+ genetic insights across peptide pathways, including variants affecting GLP-1 receptor sensitivity and metabolic stress response
More studies, with larger sample sizes and longer follow-up periods, are needed to assess the cardiovascular outcomes of semaglutide. Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes, high blood pressure, and sleep apnea
Finally, there's the integrity of the peptide itself
Genetic predispositions in appetite-regulation and metabolic pathways may provide context for why some patients experience slower progress, enabling more targeted conversations with providers about next steps
"LIP-C peptide dosage" is a broad question, and the useful answer is a framework rather than a number